GlassScriptPhysician profile
Stephanie Mcleish
NPI 1104850460
$8,300.77
in general payments reported to CMS, 2019-2025
25 companies · $98.09 in 2025
The $98.09 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $328 · 2021: $1,770 · 2022: $2,587 · 2023: $2,181 · 2024: $79.78 · 2025: $98.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.86 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,460.51 | 2019-2023 | |
| Janssen Biotech, INC. | $1,333.24 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $769.74 | 2019-2023 | Ilumya |
| Genzyme Corporation | $666.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $532.62 | 2019-2023 | |
| Lilly USA, LLC | $446.73 | 2019-2023 | Olumiant, Taltz |
| Amgen INC. | $417.10 | 2019-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $324.15 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $303.96 | 2019-2023 | Cimzia |
| Leo Pharma INC. | $278.97 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $139.90 | 2022-2024 | Opzelura |
| Pfizer INC. | $105.93 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $95.20 | 2019 | |
| Arcutis Biotherapeutics, INC. | $64.50 | 2023 | |
| Genentech USA, INC. | $62.04 | 2019-2023 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $55.12 | 2023 | Xtrac |
| Celgene Corporation | $50.23 | 2019 | |
| Biofrontera INC. | $44.67 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $36.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.11 | 2022 | |
| Sandoz INC. | $20.39 | 2023 | Hyrimoz |
| Dermavant Sciences, INC. | $19.60 | 2023 | Vtama |
| Arbor Pharmaceuticals, INC. | $14.05 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Mcleish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.